A Phase 3 interventional study of DEFINITY in Cardiac Disease, sponsored by Lantheus Medical Imaging. Completed at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-17.
Sponsored by Lantheus Medical Imaging (part of Lantheus Holdings, Inc.) · Phase 3, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 646 studies in Heart Diseases with a site in United States — 93 open to participants now, 131 under way, 5 of them phase 3. Heart Diseases · United States.
Among the 646 studies in Heart Diseases with a site in United States, this one is the 221st largest by enrollment of the 430 interventional ones that give a count, is one of 27 that started in 2018, is one of 63 in phase 3, and was the 439th registered.
2,135 studies on the registry are indexed under Heart Diseases; 251 are open to participants now.
Browse Heart Diseases studies →93 of the 646 studies in Heart Diseases with a site in United States are open now. Recruiting first, the newest first:
Barbara Ann Karmanos Cancer Institute · Sites in United States
Ages 18+
AnaCardio AB · Sites in United States, Bulgaria, Canada and 5 more countries
Ages 18–85
Abiomed Inc. · Sites in United States
Ages 18–80
Edwards Lifesciences · Sites in United States
Ages 18+
Medtronic Cardiac Ablation Solutions · Sites in United States
Ages 18–85
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 181 Heart Diseases studies recruiting now, 128 (71%) set no upper age limit and 21 (12%) stop at 75 or younger; 32 take children under 18; 42 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
646 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 38 · Phase 2 62 · Phase 3 71 · Phase 4 36
First in 1973; this study’s year is marked. 27 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 153 is above the median of 129 across 931 interventional studies indexed under Heart Diseases.
Median enrollment 161 across the 430 interventional studies, 300 across the 206 observational. Of the 469 that completed or were terminated, 158 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
184 of 646 have an industry lead sponsor. The 10 most frequent:
This study is registered under Lantheus Medical Imaging, one of the names counted as Lantheus Holdings, Inc.. Under that name alone:
Lantheus Medical Imaging is the lead sponsor of 30 studies on the registry; 3 are open to participants now.
Lantheus Holdings, Inc. has 4 studies filed under Heart Diseases — fewer than ten, so there is no comparison to draw.
40 of the studies in Heart Diseases with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06077422Phase 3Rutgers, The State University of New JerseyExparel vs. Marcaine ESP Block for Post-cardiac Surgical Pain | 2027-01-11 |
| NCT05153967Vanderbilt University Medical CenterCooperative Assessment of Late Effects for SCD Curative Therapies | 2026-11 |
| NCT06891222Mayo ClinicA Study of Electrocardiogram and Focused Cardiac Ultrasound for Enhanced Cardiac Disease Screening | 2026-11 |
| NCT06703489Medtronic Cardiac Ablation SolutionsSafety and Performance Assessment of the Sphere-9™ Catheter and Affera™ Ablation System for the Treatment of Ventricular Tachycardia (Sphere-9 VT EFS) | 2026-11 |
| NCT02694094Johns Hopkins UniversityImpact of Ketogenic Diets on Cardiovascular Health in Adults With Epilepsy | 2026-12 |
Add all 40 to your calendar (.ics) → With an account.
Among the 646 studies in Heart Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 3, prospective, open-label, multicenter study to evaluate Left Ventricular Ejection Fraction (LVEF) measurement accuracy and reproducibility of DEFINITY® contrast-enhanced and unenhanced echocardiography as compared with non-contrast cardiac magnetic resonance imaging (CMR) used as the truth standard.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Women of child-bearing potential are excluded unless they:
Unstable cardiovascular status defined as:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Each patient will undergo an unenhanced ultrasound examination and a DEFINITY contrast-enhanced ultrasound
Drug: DEFINITY
All subjects will receive a single dose of DEFINITY®
Absolute Value of LVEF Percentage Differences From CMR by Blinded Reader
Demonstrate improvement in accuracy in left ventricular ejection fraction (LVEF) assessment using Definity contrast-enhanced over unenhanced echocardiography by comparing LVEF Percentage Differences from CMR measured by 3 independent blinded image readers.
Time frame: Up to 30 days between day of echocardiograms and CMR imaging
Secondary Objective 1: Absolute Value of LVEF Percentage Differences From CMR by Blinded Reader for Suboptimal Echocardiograms
Demonstrate improvement in accuracy in left ventricular ejection fraction (LVEF) assessment using DEFINITY® contrast-enhanced over unenhanced echocardiography in subjects with suboptimal echocardiograms by comparing LVEF percentage differences from CMR measured by 3 independent readers.
Time frame: Up to 30 days between day of echocardiograms and CMR imaging
Secondary Objective 2: Absolute Value LVEF Percentage Differences From CMR Between Blinded Readers
Demonstrate a reduction in inter-reader variability for the assessment of left ventricular ejection fraction using DEFINITY® contrast-enhanced versus unenhanced echocardiography by comparing LVEF Percentage Differences from CMR between 3 independent blinded readers
Time frame: Up to 30 days between day of echocardiograms and CMR imaging
Secondary Objective 3: Absolute Value End-Diastolic and Systolic Volume Differences From CMR Between Blinded Readers
Demonstrate a reduction in inter-reader variability for the assessment of end-diastolic and systolic volumes using DEFINITY® contrast-enhanced versus unenhanced echocardiography by comparing end-diastolic and systolic volume differences from CMR between 3 independent blinded readers.
Time frame: Up to 30 days between day of echocardiograms and CMR imaging
Secondary Objective 4: Absolute Value of LVEF Percentage Differences From CMR Between Blinded Readers for Suboptimal Echocardiograms
Demonstrate a reduction in inter-reader variability for the assessment of left ventricular ejection fraction using DEFINITY® contrast-enhanced versus unenhanced echocardiography by comparing LVEF Percentage Differences from CMR between 3 independent blinded readers in subjects with suboptimal echocardiograms.
Time frame: Up to 30 days between day of echocardiograms and CMR imaging
Secondary Objective 5: Absolute Value End-Diastolic and Systolic Volume Differences From CMR Between Blinded Readers for Suboptimal Echocardiograms
Demonstrate a reduction in inter-reader variability for the assessment of end-diastolic/systolic volumes using DEFINITY® contrast-enhanced versus unenhanced echocardiography by comparing end-diastolic and systolic volume differences from CMR between 3 independent blinded readers in subjects with suboptimal echocardiograms.
Time frame: Up to 30 days between day of echocardiograms and CMR imaging
| Milestone | Definity |
|---|---|
| Started | 153 |
| Completed | 148 |
| Not completed | 5 |
Demonstrate improvement in accuracy in left ventricular ejection fraction (LVEF) assessment using Definity contrast-enhanced over unenhanced echocardiography by comparing LVEF Percentage Differences from CMR measured by 3 independent blinded image readers.
| Percent Ejection Fraction | Blinded Reader 1 | Blinded Reader 2 | Blinded Reader 3 |
|---|---|---|---|
| Echo Enhanced | 6.10 ± 5.319 | 6.38 ± 5.227 | 4.93 ± 4.288 |
| Echo Unenhanced | 6.18 ± 5.300 | 6.61 ± 5.256 | 5.36 ± 4.498 |
Demonstrate improvement in accuracy in left ventricular ejection fraction (LVEF) assessment using DEFINITY® contrast-enhanced over unenhanced echocardiography in subjects with suboptimal echocardiograms by comparing LVEF percentage differences from CMR measured by 3 independent readers.
| Percent Ejection Fraction | Blinded Reader 1 | Blinded Reader 2 | Blinded Reader 3 |
|---|---|---|---|
| Echo Enhanced | 7.48 ± 6.228 | 7.16 ± 6.337 | 5.71 ± 5.293 |
| Echo Unenhanced | 7.16 ± 6.184 | 7.12 ± 5.381 | 5.89 ± 4.523 |
Demonstrate a reduction in inter-reader variability for the assessment of left ventricular ejection fraction using DEFINITY® contrast-enhanced versus unenhanced echocardiography by comparing LVEF Percentage Differences from CMR between 3 independent blinded readers
| Percent Ejection Fraction | Blinded Reader 1 | Blinded Reader 2 | Blinded Reader 3 |
|---|---|---|---|
| Echo Enhanced | 6.10 ± 5.319 | 6.38 ± 5.227 | 4.93 ± 4.288 |
| Echo Unenhanced | 6.18 ± 0.164 | 6.61 ± 5.256 | 5.36 ± 4.498 |
Demonstrate a reduction in inter-reader variability for the assessment of end-diastolic and systolic volumes using DEFINITY® contrast-enhanced versus unenhanced echocardiography by comparing end-diastolic and systolic volume differences from CMR between 3 independent blinded readers.
| mL | Blinded Reader 1 | Blinded Reader 2 | Blinded Reader 3 |
|---|---|---|---|
| Echo Enhanced End Diastolic | 52.31 ± 35.726 | 46.57 ± 33.785 | 39.37 ± 26.206 |
| Echo Unenhanced End Diastolic | 58.02 ± 38.483 | 56.65 ± 37.766 | 48.07 ± 31.620 |
| Echo Enhanced End Systolic | 33.56 ± 28.641 | 29.93 ± 25.845 | 26.01 ± 20.740 |
| Echo Unenhanced End Systolic | 37.53 ± 30.016 | 33.51 ± 28.079 | 30.72 ± 23.534 |
Demonstrate a reduction in inter-reader variability for the assessment of left ventricular ejection fraction using DEFINITY® contrast-enhanced versus unenhanced echocardiography by comparing LVEF Percentage Differences from CMR between 3 independent blinded readers in subjects with suboptimal echocardiograms.
| Percent Ejection Fraction | Blinded Reader 1 | Blinded Reader 2 | Blinded Reader 3 |
|---|---|---|---|
| Echo Enhanced | 7.48 ± 6.228 | 7.16 ± 6.337 | 5.71 ± 5.293 |
| Echo Unenhanced | 7.16 ± 6.184 | 7.12 ± 5.381 | 5.89 ± 4.523 |
Demonstrate a reduction in inter-reader variability for the assessment of end-diastolic/systolic volumes using DEFINITY® contrast-enhanced versus unenhanced echocardiography by comparing end-diastolic and systolic volume differences from CMR between 3 independent blinded readers in subjects with suboptimal echocardiograms.
| mL | Blinded Reader 1 | Blinded Reader 2 | Blinded Reader 3 |
|---|---|---|---|
| Echo Enhanced End Diastolic | 62.34 ± 40.035 | 54.68 ± 37.571 | 45.44 ± 29.702 |
| Echo Unenhanced End Diastolic | 65.45 ± 43.227 | 63.25 ± 41.700 | 53.77 ± 34.210 |
| Echo Enhanced End Systolic | 39.52 ± 29.712 | 34.00 ± 26.955 | 30.12 ± 22.174 |
| Echo Unenhanced End Systolic | 39.45 ± 33.303 | 33.97 ± 29.233 | 32.78 ± 24.522 |
Collected over Up to 12 days: Enrolled subjects were followed for adverse events and serious adverse events from the time the Informed Consent was signed at screening (Day -7 to Day 0) through 72+/- 24 hours after completion of Definity administration (Day 0).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Definity | 0/153 (0%) | 0/153 (0%) | 0/153 (0%) |
Baseline data are calculated based on Safety Population
| Age, Categorical(Participants) | Definity |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 98 |
| >=65 years | 55 |
| Sex: Female, Male(Participants) | Definity |
|---|---|
| Female | 51 |
| Male | 102 |
| Ethnicity (NIH/OMB)(Participants) | Definity |
|---|---|
| Hispanic or Latino | 18 |
| Not Hispanic or Latino | 135 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Definity |
|---|---|
| American Indian or Alaska Native | 2 |
| Asian | 3 |
| Native Hawaiian or Other Pacific Islander | 4 |
| Black or African American | 37 |
| White | 104 |
| More than one race | 3 |
| Unknown or Not Reported | 0 |
| LVEF Group(Participants) | Definity |
|---|---|
| LVEF <30% | 35 |
| LVEF 30-40% | 40 |
| LVEF 41-50% | 39 |
| LVEF >50% | 39 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2018 to primary completion in Aug 2019, 10 months.
Results were first posted in Dec 2020, 1 year 3 months after primary completion.
Of 32 phase 3 interventional studies under Heart Diseases, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 58. This study's 10 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Perflutren